Latest Period
n/a
Security Snapshot
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 Institutional Ownership
CUSIP: 45845PAA6
13F Institutional Holders and Ownership History from Q2 2016 to Q3 2023
Institutions Reporting
Principal
Price (% of par)
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Debt / NOTE 3.250% 7/0
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 is tracked under CUSIP 45845PAA6.
- Latest finished 13F holder period is not available.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 4 to 0 between Q2 2023 and Q3 2023.
- SEC-reported value moved from $10,109,022 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
45845PAA6
Latest holder period
n/a
13F holders
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45845PAA6:
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
30
Latest
n/a
Rows shown
1-25 of 30
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2023 Q3 | $0 | $0 | -$10,109,022 | 0 | |
| 2023 Q2 | $9,719,000 | $10,109,022 | -$86,491,702 | 100.49% | 4 |
| 2023 Q1 | $96,946,832 | $96,458,698 | +$4,661,082 | 99.25% | 17 |
| 2022 Q4 | $92,301,155 | $90,837,870 | +$10,574,603 | 98.02% | 22 |
| 2022 Q3 | $77,140,000 | $76,143,830 | +$562,793 | 97.12% | 19 |
| 2022 Q2 | $76,577,000 | $75,591,990 | -$18,743,825 | 97.0% | 19 |
| 2022 Q1 | $82,929,667 | $90,481,476 | +$3,530,752 | 92.0% | 23 |
| 2021 Q4 | $82,778,227 | $79,161,051 | -$6,465 | 94.68% | 24 |
| 2021 Q3 | $84,114,142 | $77,029,805 | -$293,537,003 | 90.18% | 26 |
| 2021 Q2 | $411,323,279 | $370,232,428 | -$21,064,846 | 90.0% | 33 |
| 2021 Q1 | $449,991,048 | $373,710,879 | -$3,654,814 | 82.0% | 41 |
| 2020 Q4 | $438,570,500 | $343,421,900 | -$798,028 | 77.78% | 35 |
| 2020 Q3 | $469,032,500 | $379,338,906 | +$2,391,122 | 80.48% | 46 |
| 2020 Q2 | $445,347,500 | $334,279,014 | +$4,648,311 | 75.26% | 45 |
| 2020 Q1 | $443,068,500 | $361,104,934 | +$7,505,037 | 81.16% | 49 |
| 2019 Q4 | $433,084,208 | $438,750,527 | +$11,216,577 | 100.84% | 44 |
| 2019 Q3 | $428,672,000 | $370,347,732 | +$12,065,929 | 86.02% | 44 |
| 2019 Q2 | $417,577,832 | $386,205,424 | -$39,428,176 | 89.21% | 48 |
| 2019 Q1 | $454,934,000 | $451,601,140 | +$30,882,740 | 99.15% | 48 |
| 2018 Q4 | $424,884,000 | $389,544,000 | +$9,159,433 | 92.31% | 43 |
| 2018 Q3 | $418,404,000 | $422,410,019 | +$54,142,363 | 101.01% | 44 |
| 2018 Q2 | $358,964,000 | $315,021,000 | -$1,913,901 | 87.88% | 43 |
| 2018 Q1 | $363,982,000 | $292,060,000 | +$2,559,573 | 80.5% | 43 |
| 2017 Q4 | $366,010,000 | $293,730,000 | -$19,654,894 | 80.0% | 45 |
| 2017 Q3 | $391,549,000 | $304,651,000 | -$475,345 | 77.74% | 49 |